Bristol Myers Squibb
American pharmaceutical company
Follow Bristol Myers Squibb on Notably News to receive short updates to your email — rarely!
| 2024 | Bristol Myers Squibb acquired Mirati Therapeutics, Karuna Therapeutics, and RayzeBio. |
| September 26 2024 | FDA approved Cobenfy, BMS's novel schizophrenia drug, the first new treatment for the disorder in 70 years. |
| 2023 | Bristol Myers Squibb, along with Johns Hopkins University and the Rockefeller Foundation, became defendants in a $1 billion lawsuit from Guatemala related to unethical syphilis experiments conducted in the 1940s that infected hundreds of Guatemalans. |
| December 2023 | BMS signed an agreement to acquire Karuna Therapeutics for $14 billion, including their lead asset KarXT, an investigational muscarinic antipsychotic. |
| October 2023 | BMS agreed to acquire Mirati Therapeutics, an American biotechnology company developing cancer therapies, in an all-cash deal worth $4.8 billion. |
| August 2023 | BMS partnered with Cellares for robotic production of CAR-T treatments. |
| August 28 2023 | FDA approved label expansion for Reblozyl (Luspatercept), making it a first-line treatment for anemia in adults with low- to intermediate-risk myelodysplastic syndromes (MDS). The approval was supported by data from the Phase III COMMANDS study, highlighting the drug's potential to become a $4 billion sales product by 2030. |
| 2022 | Bristol Myers Squibb reported a total revenue of $46.2 billion for the fiscal year, maintaining its position as one of the world's largest pharmaceutical companies. |
| June 2022 | BMS announced acquisition of Turning Point Therapeutics Inc for $4.1 billion to boost its cancer drug portfolio, specifically repotrectinib. |
| 2021 | Bristol Myers Squibb sponsored the CARE Faculty's Winter Hematology Update event, demonstrating their engagement with medical specialist coalitions in Oakville, Ontario. |
| 2020 | Bristol Myers Squibb acquired Forbius and MyoKardia. |
| October 2020 | BMS announced acquisition of cardiology company MyoKardia for $13.1 billion, gaining control of mavacamten and two key treatment developments. |
| July 2020 | Fostemsavir (BMS-663068) received approval in the United States, marking a significant milestone for the company's pharmaceutical development. |
| February 2020 | BMS and partner Biomotiv launched Anteros Pharmaceuticals, a new company focusing on inflammation and fibrosis medicines. |
| January 2019 | BMS announced acquisition of Celgene for $74 billion ($95 billion including debt), becoming the largest pharmaceutical-company acquisition ever, aimed at refreshing the company's pipeline. |
| 2018 | Bristol Myers Squibb acquired Impact Biomedicines and Juno Therapeutics. |
| April 2018 | Reported first quarter net income of $1.5 billion (91 cents per share), driven by increased sales of cancer drug Opdivo. |
| 2017 | Bristol Myers Squibb acquired IFM Therapeutics and Delinia. |
| August 2017 | BMS acquired IFM Therapeutics for $300 million upfront, with contingency payments of $1.01 billion, to better compete against Merck & Co's cancer treatment Keytruda. |
| February 2017 | Activist investor Carl Icahn took a stake in the company, signaling potential future takeover interest. |
| 2016 | Bristol Myers Squibb acquired Padlock Therapeutics, Cormorant Pharmaceuticals, EngMab AG, AbVitro, and RedoxTherapies. |
| March 2016 | BMS announced acquisition of Padlock Therapeutics for up to $600 million. |
| 2015 | Bristol Myers Squibb acquired Flexus Biosciences, Cardioxyl, Quanticel, and Receptos. |
| November 2015 | BMS acquired cardiovascular disease drug developer Cardioxyl for up to $2.075 billion, strengthening its pipeline with the phase II candidate for acute decompensated heart failure, CXL-1427. |
| May 2015 | Dr. Giovanni Caforio became CEO of the company, succeeding Andreotti, after serving as the company's COO. |
| March 2015 | Obtained an exclusive opportunity to license and commercialize PROSTVAC, a prostate-specific antigen cancer immunotherapy from Bavarian Nordic, with potential payments up to $975 million. |
| February 2015 | BMS acquired Flexus Biosciences for $1.25 billion, gaining full rights to Flexus' lead small molecule IDO1-inhibitor, F001287. |
| February 2015 | Initiated a research partnership with Rigel Pharmaceuticals that could generate more than $339 million. |
| December 2014 | Received FDA approval for nivolumab (Opdivo), a PD-1 inhibitor for treating patients with inoperable or treatment-resistant skin cancer. |
| April 2014 | BMS announced acquisition of iPierian for up to $725 million. |
| 2013 | Forbes magazine ranked Bristol-Myers Squibb as the best drug company, citing a market capitalization of US$87 billion and stock appreciation of 61.4%. |
| 2012 | Bristol Myers Squibb acquired Inhibitex Inc, Avila Therapeutics, Inc, and jointly acquired Amylin Pharmaceuticals with AstraZeneca. |
| 2011 | A U.S. court dismissed a lawsuit against the U.S. government regarding the Guatemala syphilis experiments, ruling that the government could not be held liable for actions committed outside of the United States. |
| 2010 | Bristol Myers Squibb acquired ZymoGenetics and Abraxis BioScience Inc. |
| 2010 | Lou Schmukler joined Bristol-Myers Squibb as the president of global product development and design, leading the team that completed the company's strategic transformation to a specialty biopharmaceutical company. |
This contents of the box above is based on material from the Wikipedia article Bristol Myers Squibb, which is released under the Creative Commons Attribution-ShareAlike 4.0 International License.